Audentes Therapeutics Inc (BOLD.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|45||President, Chief Executive Officer, Co-Founder, Director|
|56||2013||Co-Founder, Independent Director|
|49||2017||Chief Financial Officer, Senior Vice President|
|43||2015||Chief Operating Officer, Senior Vice President|
|63||2015||Senior Vice President - Human Resources and Corporate Affairs|
- BRIEF-Audentes Therapeutics Q4 Loss Per Share $0.82
- BRIEF-Wellington Management Group Llp Reports 10.85 pct Passive Stake In Audentes Therapeutics As Of Jan 31, 2018
- BRIEF-Audentes Therapeutics Says Public Offering Of 5.75 Mln Shares Priced At $35/Share
- BRIEF-Audentes Therapeutics To Offer $150 Million Of Common Stock In Public Offering
- BRIEF-Audentes Announces Positive Interim Data From First Dose Cohort Of Aspiro